A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Santalum album (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Santalis Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2017 Protocol was amended to change in the treatment arms and change in status from active no longer recruiting to recruiting of the trial .
    • 24 Oct 2017 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
    • 24 Oct 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top